Is a CHMP positive opinion the same as approval?

No. It is a scientific recommendation; the European Commission takes the legal decision afterwards, usually following it.

Which strengths were recommended?

Tablets for oral use in 1.5 mg, 4 mg, 9 mg and 25 mg.

Research & Regulatory News

The EMA Opinion on Oral Semaglutide for Weight Management

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

On 21 May 2026 the CHMP adopted a positive opinion recommending an extension to Wegovy's marketing authorisation, adding tablets for oral use in four strengths — 1.5 mg, 4 mg, 9 mg and 25 mg. It would be the first GLP-1 receptor agonist for weight management developed for oral use.

Key facts

Opinion adopted: 21 May 2026
Meeting: CHMP, 18–21 May 2026
Type: Variation — new pharmaceutical form and route
Strengths: 1.5 mg, 4 mg, 9 mg, 25 mg
Existing form: Weekly subcutaneous injection
Status: Opinion, not yet a decision

What a CHMP positive opinion is

A recommendation from the EMA's scientific committee, not the authorisation itself. The European Commission takes the legal decision afterwards, and it follows the opinion in the great majority of cases. Reporting a positive opinion as an approval is a common and slightly premature conflation.

What specifically was recommended

A variation adding a new pharmaceutical form with a new route of administration — tablets for oral use, in four strengths: 1.5 mg, 4 mg, 9 mg and 25 mg. This extends an existing authorisation rather than creating a new one, since Wegovy is already authorised as a weekly subcutaneous injection.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

A distinction worth getting right

Secondary coverage has described this opinion as covering oral Wegovy and a 7.2 mg pen together. It does not. The recommendation concerns oral tablets in the four strengths listed. The 7.2 mg figure belongs to STEP UP, a separate phase 3b trial of a higher-dose once-weekly injectable — a different formulation, a different route and a different regulatory question.

Why an oral peptide is difficult

Peptides are digested. Oral semaglutide addresses this with the absorption enhancer SNAC and strict administration conditions, and even then absorption is a small and variable fraction of the dose. That is why the tablet strengths are so much larger than the injectable dose — the numbers are not comparable across routes.

How this sits against the small molecules

Orforglipron and aleniglipron avoid the problem by not being peptides at all, so they need no absorption enhancer and no administration conditions. Oral semaglutide keeps peptide pharmacology and solves delivery by formulation. Both routes to an oral GLP-1 are now real, and they involve entirely different trade-offs.

What this does not concern

Research material. This is a regulatory step for a licensed medicine assessed by the EMA. Nothing supplied here is semaglutide in any form, and no research compound is an alternative to a prescribed weight-management medicine.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is a CHMP positive opinion the same as approval?: No. It is a scientific recommendation; the European Commission takes the legal decision afterwards, usually following it.
Which strengths were recommended?: Tablets for oral use in 1.5 mg, 4 mg, 9 mg and 25 mg.
Does the opinion include a 7.2 mg pen?: No. That figure belongs to STEP UP, a separate trial of a higher-dose once-weekly injectable — a different route and a different regulatory question.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum